News Search Results
Jun 16, 2025, 10:05 ET Shasqi Publishes Landmark Study in Clinical Cancer Research: First-in-Human Use of Click Chemistry Unlocks New Opportunities for Targeted Cancer Therapies
of other cancer therapeutics such as radiopharmaceutical therapy." About ShasqiShasqi, Inc. is a preclinical biotechnology company whose focus is to make cancer drugs more effective with pre-targeting enabled by click chemistry, a 2022 Nobel Prize winning innovation.
More news about: Shasqi, Inc.
Jun 16, 2025, 08:20 ET Cresilon Announces International Distribution Agreement for VETIGEL with McCarthy Vet
June 16, 2025 /PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into a distribution agreement for VETIGEL® to be sold
More news about: Cresilon
Jun 16, 2025, 08:08 ET "Luminous Path, Shared Stride - Brazil and China"
https://www.prnewswire.com/news-releases/luminous-path-shared-stride--brazil-and-china-302482141.html SOURCE SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD
More news about: SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD
Jun 16, 2025, 08:00 ET Precisio Biotix Therapeutics, Inc. (Precisio) Announces a Grant for the Discovery of Novel Engineered Lysin Antimicrobials Targeting Bacterial Vaginosis Associated Pathobionts (BV)
engineered lysins with potent activity against the major bacterial pathogens causing bacterial vaginosis (BV). Precisio is an American biotechnology company developing pathogen-specific lysin biotherapeutics and antibacterials using computational protein designs and related high-tech platforms.
More news about: Precisio Biotix Therapeutics, Inc.
Jun 16, 2025, 08:00 ET Hoth Therapeutics to Attend 2025 BIO International Convention
The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe. To learn more about this event visit
More news about: Hoth Therapeutics, Inc.
Jun 16, 2025, 07:15 ET ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)
B-cell malignancies and earlier lines of therapy. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company helping to improve the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company
More news about: ADC Therapeutics SA
Jun 16, 2025, 07:00 ET Solu Therapeutics Appoints Enda Moran, PhD, MBA as Chief Operating Officer
BOSTON, June 16, 2025 /PRNewswire/ -- Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the appointment
More news about: Solu Therapeutics
Jun 16, 2025, 07:00 ET NUZ-001 Shows Promise in Zebrafish Model of Huntington's Disease
Neurizon Therapeutics Limited. About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment
More news about: Neurizon Therapeutics Limited
Jun 16, 2025, 06:45 ET Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jun 16, 2025, 04:00 ET Clarivate Identifies Radioligand Therapy Innovators as Companies to Watch in the Future of Precision Oncology
through advancements in radioligand therapies (RLTs)—a rapidly evolving class of therapeutics that combines nuclear medicine with precision-targeted biotechnology to treat cancer with heightened specificity. Drawing on proprietary data, expert analysis and insights into therapeutic benefit, financing activity
More news about: Clarivate Plc
Jun 16, 2025, 04:00 ET Clarivate Identifies Radioligand Therapy Innovators as Companies to Watch in the Future of Precision Oncology
through advancements in radioligand therapies (RLTs)—a rapidly evolving class of therapeutics that combines nuclear medicine with precision-targeted biotechnology to treat cancer with heightened specificity. Drawing on proprietary data, expert analysis and insights into therapeutic benefit, financing activity
More news about: Clarivate Plc
Jun 16, 2025, 02:03 ET FTRE Shareholders with Large Losses are Encouraged to Seek Counsel - Contact Robbins LLP for Information About Leading the Class Action Against Fortrea Holdings, Inc.
global contract research organization ("CRO") that provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers.
More news about: Robbins LLP
Jun 15, 2025, 21:00 ET ArkBio's New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA
Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture capital institutions. For more information about the company, please visit our website：
More news about: Arkbio
Jun 15, 2025, 21:00 ET ArkBio's New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA
Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture capital institutions. For more information about the company, please visit our website：
More news about: Arkbio
Jun 15, 2025, 19:30 ET Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients
ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information,
More news about: Celltrion
Jun 15, 2025, 12:30 ET FTRE INVESTOR DEADLINE: Robbins Geller Rudman & Dowd Announces that Fortrea Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
global clinical research organization ("CRO") that provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers. According to the complaint, in June 2023, Labcorp Holdings Inc. spun off Fortrea as
More news about: Robbins Geller Rudman & Dowd LLP
Jun 15, 2025, 10:30 ET INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Fortrea Holdings
from buy to hold. Among other things, the Jefferies Report cited perceived weaknesses in the Company's business model as a CRO amid pressure on biotechnology funding and suggested that the cost savings Fortrea expects to achieve by exiting the TSAs are "not as material as [o]ne [m]ight think," stating
More news about: Faruqi & Faruqi, LLP
Jun 13, 2025, 19:00 ET Rakuten Medical Selected to Participate in FDA CEO Forum in San Diego
DIEGO, June 13, 2025 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that it was selected by the U.S. Food and Drug
More news about: Rakuten Medical, Inc.
Jun 13, 2025, 16:54 ET INVESTIGATION ALERT: Edelson Lechtzin LLP is investigating GeneDx Holdings Corp. (NASDAQ: WGS) and Encourages Investors with Substantial Losses to Contact the Firm
[email protected]. THE COMPANY: GeneDx is a biotechnology company specializing in clinical diagnostic services for rare and pediatric genetic disorders. THE ALLEGED WRONGDOING:
More news about: Edelson Lechtzin LLP
Jun 13, 2025, 16:00 ET Innocan Pharma Highlights Breakthrough Narrative Review on Liposomal Synthetic CBD for Chronic Pain: A Novel Non-Opioid Analgesic Approach
2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries proudly announces the third party publication of a peer-reviewed narrative review in Cureus journal titled "Considering Long-Acting Synthetic
More news about: Innocan Pharma Corporation
Jun 13, 2025, 16:00 ET Innocan Pharma Highlights Breakthrough Narrative Review on Liposomal Synthetic CBD for Chronic Pain: A Novel Non-Opioid Analgesic Approach
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries proudly announces the third party publication of a peer-reviewed narrative review in Cureus journal titled "Considering Long-Acting Synthetic
More news about: Innocan Pharma Corporation
Jun 13, 2025, 13:34 ET Billions in Deals Reshaping the Cell and Gene Therapy Industry, reports Kalorama Information
Information, part of Science and Medicine Group, is a trusted source of market research in the life sciences. With a focus on in vitro diagnostics, biotechnology, and medical devices, Kalorama reports are used by top healthcare companies, government agencies, and investment firms worldwide. For purchase
More news about: Kalorama Information
Jun 13, 2025, 11:45 ET Investor ESG Software Market Size is reaching US$ 3.36 billion by USD 3.36 billion by 2031| CAGR 17.6%
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Jun 13, 2025, 11:21 ET Welded Steel Tubes Market Size is Projected to reach US$ 274.25 billion by 2031 | CAGR 5.6%
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Jun 13, 2025, 11:01 ET Electronic Warfare Market Size to Hit $34.10 Billion by 2034, Experiences Growth in Business Aviation Sector | CAGR of 9.4%
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Trending
More news about: The Insight Partners